PTX3 and neoplasm: The ongoing effort to define the relationship more comprehensively between RCC cells and the various immuno-inflammatory host responses, has recently been additionally bolstered by an extensive analysis of the potential roles of complement system activation within the ccRCC TME, centered around the quantification of expression levels for Pentraxin-3 (PTX3), an innate immune regulator, both in ccRCC tumor samples and patient serum.